Use of C2-substituted indan-1-ol systems for preparing medicaments for the prophylaxis or treatment of obesity

1. A method of reducing weight in a mammal in need thereof comprising administering to the mammal at least one compound chosen from at least one compound of the formula (I)

in which

R1, R2, R3, R4 independently of one another are H, F, Cl, Br, I, CN; N 3 , NO 2 , OH, O(C 1 -C 8 )-alkyl, O(C 3 -C 4 and C 6 -C 8 )-cycloalkyl, O—CH 2 -phenyl, O-phenyl, O—CO—(C 1 -C 8 )-alkyl, O—CO—(C 3 -C 8 )-cycloalkyl, S(O) 0-2 (C 1 -C 8 )-alkyl, S(O) 0-2 (C 3 -C 8 )-cycloalkyl, NH 2 , NH—(C 1 -C 8 )-alkyl, NH—(C 3 -C 8 )-cycloalkyl, N[(C 1 -C 8 )-alkyl] 2 , N[(C 3 -C 8 )-cycloalkyl] 2 , NH—CO—(C 1 -C 8 )-alkyl, NH—CO—(C 3 -C 8 )-cycloalkyl, SO 3 H, SO 2 —NH 2 , SO 2 —NH—(C 1 -C 8 )-alkyl, SO 2 —NH—(C 3 -C 8 )-cycloalkyl, NH—SO 2 —NH 2 , NH—SO 2 —(C 1 -C 8 )-alkyl, NH—SO 2 —(C 3 -C 8 )-cycloalkyl, O—CH 2 —COOH, O—CH 2 —CO—O(C 1 -C 8 )-alkyl, COOH, CO—O(C 1 -C 8 )-alkyl, CO—O—(C 3 -C 8 )-cycloalkyl, CO—NH 2 , CONH(C 1 -C 8 )-alkyl, CO—N[(C 1 -C 8 )-alkyl] 2 , (C 1 -C 8 )-alkyl, (C 3 -C 8 )-cycloalkyl, (C 2 -C 8 )-alkenyl, (C 2 -C 8 )-alkynyl, wherein the alkyl, cycloalkyl, alkenyl and alkynyl groups in each case have zero to seven hydrogen atoms replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH 3 , O—CH 2 -Ph, NH 2 , NH—CO—CH 3 or N(COOCH 2 Ph) 2 ; or

phenyl, 1- or 2-naphthyl,

5-tetrazolyl, 1-[(C 1 -C 6 )-alkyl]-5-tetrazolyl,

2-[(C 1 -C 6 )-alkyl]-5-tetrazolyl;

1-imidazolyl,

1- or 4-[1,2,4]-triazolyl,

2- or 3-thienyl,

2- or 3-furyl,

2-, 3- or 4-pyridyl,

2-, 4- or 5-oxazolyl,

3-, 4- or 5-isoxazolyl,

2-, 4- or 5-thiazolyl,

2-, 4- or 5-isothiazolyl

where the aryl radical or heterocycle is unsubstituted or substituted one to two times by F, Cl, Br, CN, OH, (C 1 -C 4 )-alkyl, CF 3 , O—(C 1 -C 4 )-alkyl, S(O) 0-2 (C 1 -C 6 )-alkyl, NH 2 , NH—SO 2 —(C 1 -C 4 )-alkyl, COOH, CO—O—(C 1 -C 4 )-alkyl, CO—NH 2 ,

wherein the alkyl groups in each case have zero to seven hydrogen atoms replaced by fluorine;

or R2 and R3 together form the group —O—CH 2 —O—;

X is S, SO, or SO 2 ;

Y is (CH 2 ) p , where p is 0, 1, 2 or 3;

R5 is CF 3 , (C 1 -C 18 )-alkyl, or (C 3 -C 8 )-cycloalkyl, wherein the alkyl groups in each case have zero to seven hydrogen atoms replaced by fluorine;

(CH 2 ) r COR6, where r is 1-6 and R6 is OH, O—(C 1 -C 6 )-alkyl or NH 2 ;

CH 2 —CH(NHR7)—COR8, where R7 is H, C(O)—(C 1 -C 4 )-alkyl or C(O)O—(C 1 -C 4 )-alkyl and R8 is OH, O—(C 1 -C 6 )-alkyl or NH 2 ; or

phenyl, 1- or 2-naphthyl, biphenyl or a heterocyclic radical, where the rings or ring systems are unsubstituted or substituted one or two

times by F, Cl, Br, I, CN, OH, O(C 1 -C 8 )-alkyl, O(C 3 -C 8 )-cycloalkyl, O—CO—(C 1 -C 8 )-alkyl, O—CO—(C 3 -C 8 )-cycloalkyl, S(O) 0-2 (C 1 -C 8 )-alkyl, S(O) 0-2 (C 3 -C 8 )-cycloalkyl, NH 2 , NH—(C 1 -C 8 )-alkyl, NH—(C 3 -C 8 )-cycloalkyl, N[(C 1 -C 8 )-alkyl] 2 , N[(C 3 -C 8 )-cycloalkyl] 2 , NH—CO—(C 2 -C 8 )-alkyl, NH—CO—(C 3 -C 8 )-cycloalkyl, SO 3 H; SO 2 —NH 2 , SO 2 —NH—(C 1 -C 8 )-alkyl, SO 2 —NH—(C 3 -C 8 )-cycloalkyl, NH—SO 2 —NH 2 , NH—SO 2 —(C 1 -C 8 )-alkyl, NH—SO 2 —(C 3 -C 8 )-cycloalkyl, O—CH 2 —COOH, O—CH 2 —CO—O(C 1 -C 8 )-alkyl, COOH, CO—O(C 1 -C 8 )-alkyl, CO—O—(C 3 -C 8 )-cycloalkyl, CO—NH 2 , CONH(C 1 -C 8 )-alkyl, CO—N[(C 1 -C 8 )-alkyl] 2 , (C 1 -C 8 )-alkyl, (C 3 -C 8 )-cycloalkyl, where in the alkyl and cycloalkyl groups in each case have zero to seven hydrogen atoms replaced by fluorine;

or a physiologically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

2. The method of claim 1 , wherein

R1, R4 independently of one another are

H, F, Cl, Br, I, CN, N 3 , NO 2 , OH, O(C 1 -C 8 )-alkyl, O(C 3 -C 4 and C 6 -C 8 )-cycloalkyl, O—CH 2 -phenyl, O-phenyl, O—CO—(C 1 -C 8 )-alkyl, O—CO—(C 3 -C 8 )-cycloalkyl, S(O) 0-2 (C 1 -C 8 )-alkyl, S(O) 0-2 (C 3 -C 8 )-cycloalkyl, NH 2 , NH—(C 1 -C 8 )-alkyl, NH—(C 3 -C 8 )-cycloalkyl, N[(C 1 -C 8 )-alkyl] 2 , N[(C 3 -C 8 )-cycloalkyl] 2 , NH—CO—(C 1 -C 8 )-alkyl, NH—CO—(C 3 -C 8 )-cycloalkyl, SO 3 H, SO 2 —NH 2 , SO 2 —NH—(C 1 -C 8 )-alkyl, SO 2 —NH—(C 3 -C 8 )-cycloalkyl, NH—SO 2 —NH 2 , NH—SO 2 —(C 1 -C 8 )-alkyl, NH—SO 2 —(C 3 -C 8 )-cycloalkyl, O—CH 2 —COOH, O—CH 2 —CO—O(C 1 -C 8 )-alkyl, COOH, CO—O(C 1 -C 8 )-alkyl, CO—O—(C 3 -C 8 )-cycloalkyl, CO—NH 2 , CO—NH(C 1 -C 8 )-alkyl, CO—N[(C 1 -C 8 )-alkyl] 2 , (C 1 -C 8 )-alkyl, (C 3 -C 8 )-cycloalkyl, (C 2 -C 8 )-alkenyl, (C 2 -C 8 )-alkynyl, where in the alkyl, cycloalkyl, alkenyl and alkynyl groups in each case have zero to seven hydrogen atoms replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH 3 , O—CH 2 -Ph, NH 2 , NH—CO—CH 3 or N(COOCH 2 Ph) 2 ; or

phenyl, 1- or 2-naphthyl,

5-tetrazolyl, 1-[(C 1 -C 6 )-alkyl]-5-tetrazolyl, 2-[(C 1 -C 6 )-alkyl]-5-tetrazolyl,

1-imidazolyl,

1- or 4-[1,2,4]-triazolyl,

1- or 3-thienyl,

2- or 3-furyl,

2-, 3- or 4-pyridyl,

2-, 4- or 5-oxazolyl,

2-, 4- or 5-isoxazolyl,

2-, 4- or 5-thiazolyl, or

2-, 4- or 5-isothiazolyl

where the aryl radical or heterocycle are unsubstituted or substituted one or two times by

F, Cl, Br, CN,

OH, (C 1 -C 4 )-alkyl, CF 3 , O—(C 1 -C 4 )-alkyl,

S(O) 0-2 (C 1 -C 6 )-alkyl, NH 2 , NH—SO 2 —(C 1 -C 4 )-alkyl,

COOH, CO—O—(C 1 -C 4 )-alkyl, or CO—NH 2 wherein the alkyl groups in each case have zero to seven hydrogen atoms replaced by fluorine;

R2, R3 independently of one another are

H, F, Cl, Br, I, CN, N 3 , NO 2 , O(C 1 -C 8 )-alkyl, O(C 3 -C 8 )-cycloalkyl, O—CO—(C 1 -C 8 )-alkyl, O—CO—(C 3 -C 8 )-cycloalkyl, S(O) 0-2 (C 1 -C 8 )-alkyl, S(O) 0-2 (C 3 -C 8 )-cycloalkyl, NH 2 , NH—(C 1 -C 8 )-alkyl, NH—(C 3 -C 8 )-cycloalkyl, N[(C 1 -C 8 )-alkyl] 2 , N[(C 3 -C 8 )-cycloalkyl] 2 , NH—CO—(C 1 -C 8 )-alkyl, NH—CO—(C 3 -C 8 )-cycloalkyl, SO 3 H, SO 2 —NH 2 , SO 2 —NH—(C 5 -C 8 )-alkyl, SO 2 —NH—(C 3 -C 8 )-cycloalkyl, NH—SO 2 —NH 2 , NH—SO 2 —(C 1 -C 8 )-alkyl, NH—SO 2 —(C 5 -C 8 )-cycloalkyl, O—CH 2 —COOH, O—CH 2 —CO—O(C 1 -C 8 )-alkyl, COOH, CO—O(C 1 -C 8 )-alkyl, CO—O—(C 3 -C 8 )-cycloalkyl, CO—NH 2 , CONH(C 1 -C 8 )-alkyl, CO—N[(C 1 -C 8 )-alkyl] 2 , (C 1 -C 8 )-alkyl, (C 3 -C 8 )-cycloalkyl, (C 2 -C 8 )-alkenyl, (C 2 -C 8 )-alkynyl, where in the alkyl, cycloalkyl, alkenyl and alkynyl groups in each case have zero to seven hydrogen atoms replaced by fluorine,

or one hydrogen may be replaced by OH, OC(O)CH 3 , O—CH 2 -Ph, NH 2 , NH—CO—CH 3 or N(COOCH 2 Ph) 2 ; or

phenyl, 1- or 2-naphthyl,

5-tetrazolyl,

1-[(C 1 -C 6 )-alkyl]-5-tetrazolyl,

2-[(C 1 -C 6 )-alkyl]-5-tetrazolyl,

1imidazolyl,

1- or 4-[1,2,4]-triazolyl,

1- or 3-thienyl,

2- or 3-furyl,

2-, 3- or 4-pyridyl,

2-, 4- or 5-oxazolyl,

3-, 4- or 5-isoxazolyl,

2-, 4- or 5-thiazolyl, or

3-, 4- or 5-isothiazolyl

where the heterocycle is unsubstituted or substituted one or two times by F, Cl, Br, CN, OH, (C 1 -C 4 )-alkyl, CF 3 , O—(C 1 -C 4 )-alkyl, S(O) 0-2 (C 1 -C 6 )-alkyl, NH 2 , NH—SO 2 —(C 1 -C 4 )-alkyl,

COOH, CO—O—(C 1 -C 4 )-alkyl, or CO—NH 2 wherein the alkyl groups in each case have zero to seven hydrogen atoms replaced by fluorine;

or R2 and R3 together form the group —O—CH 2 —O—;

where in each case at least one of the radicals R1, R2, R3 and R4 is different from hydrogen;

X is S, SO, or SO 2 ;

Y is (CH 2 ) p , where p is 0, 1, 2 or 3;

R5 is (C 1 -C 18 )-alkyl, or (C 3 -C 4 - and C 6 -C 8 )-cycloalkyl, wherein the alkyl or cycloalkyl groups in each case have zero to seven hydrogen atoms replaced by fluorine;

(CH 2 ) r COR6, where r is 1-6 and R6 is OH, O—(C 1 -C 6 )-alkyl or NH 2 ;

CH 2 —CH(NHR7)-COR8, where R7 is H, C(O)—(C 1 -C 6 )-alkyl or C(O)O—(C 1 -C 6 )-alkyl and R8 is OH, O—(C 1 -C 6 )-alkyl or NH 2 ;

phenyl, 1- or 2-naphthyl, biphenyl or a heterocyclic radical, where the rings or ring systems are unsubstituted or substituted up to two times by O(C 1 -C 8 )-alkyl, O(C 3 -C 8 )-cycloalkyl, O—CO—(C 1 -C 8 )-alkyl, O—CO—(C 3 -C 8 )-cycloalkyl, S(O) 0-2 (C 1 -C 8 )-alkyl, S(O) 0-2 (C 3 -C 8 )-cycloalkyl, NH 2 , NH—(C 1 -C 8 )-alkyl, NH—(C 3 -C 8 )-cycloalkyl, N[(C 1 -C 8 )-alkyl] 2 , N[(C 3 -C 8 )-cycloalkyl] 2 , NH—CO—(C 2 -C 8 )-alkyl, NH—CO—(C 3 -C 8 )-cycloalkyl, SO 3 H, SO 2 —NH 2 , SO 2 —NH—(C 1 -C 8 )-alkyl, SO 2 —NH—(C 3 -C 8 )-cycloalkyl, NH—SO 2 —NH 2 , NH—SO 2 —(C 1 -C 8 )-alkyl, NH—SO 2 —(C 3 -C 8 )-cycloalkyl, O—CH 2 —COOH, O—CH 2 —CO—O(C 1 -C 8 )-alkyl, COOH, CO—O(C 1 -C 8 )-alkyl, CO—O—(C 3 -C 8 )-cycloalkyl, CO—NH 2 , CO—NH(C 1 -C 8 )-alkyl, CO—N[(C 1 -C 8 )-alkyl] 2 , (C 1 -C 8 )-alkyl, or (C 3 -C 8 )-cycloalkyl, where in the alkyl and cycloalkyl groups in each case have zero to seven hydrogen atoms replaced by fluorine;

or a physiologically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

3. The method of claim 1 , wherein

R1, R4 independently of one another are H, F, Cl, or Br;

R2, R3 independently of one another are

H, F, Cl, Br, CN, CONH 2 , NH—SO 2 —(C 1 -C 8 )-alkyl, O—(C 1 -C 8 )-alkyl, COOH, (C 1 -C 8 )-alkyl, (C 1 -C 8 )-alkenyl, or (C 1 -C 8 )-alkynyl, where in the alkyl, alkenyl and alkynyl groups in each case have zero to seven hydrogen atoms replaced by fluorine; or

phenyl or 1-imidazolyl; where the rings are unsubstituted or substituted one or two times by

F, Cl, Br, CN, OH, (C 1 -C 4 )-alkyl, CF 3 , O—(C 1 -C 4 )-alkyl,

wherein the alkyl groups in each case have zero to seven hydrogen atoms may be replaced by fluorine;

where in each case at least one of the radicals R1, R2, R3 and R4 is different from hydrogen;

X is S, SO, or SO 2 ;

Y is (CH 2 ) p , where p is 0 or 1;

R5 is (C 1 -C 18 )-alkyl, or (C 3 -C 4 — and C 6 -C 8 )-cycloalkyl, wherein the alkyl or cycloalkyl groups have zero to seven hydrogen atoms replaced by fluorine;

(CH 2 ) r CO—O—(C 1 -C 6 )-alkyl, where r is 1-6;

CH 2 —CH(NHR7)-COR8, where R7 is H, C(O)—(C 1 -C 4 )-alkyl or C(O)O(C 1 -C 4 )-alkyl and R8 is OH, O—(C 1 -C 6 )-alkyl or NH 2 ;

phenyl, or a heterocyclic radical;

or a physiologically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

4. The method of claim 1 , wherein

R1 is H,

R2 is Cl,

R3 is H,

R4 is H,

R5 is CH 3 ,

X is SO 2 , and

Y is (CH 2 ) p where p is 0

or a physiologically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

5. The method of claim 1 , wherein

R1 is H,

R2 is Cl,

R3 is H,

R4 is H, R5 is

CH 3 ,

X is S, and

Y is (CH 2 ) p where p is 0

or a physiologically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

6. The method of claim 1 , wherein

R1 is H,

R2 is Cl,

R3 is H,

R4 is H,

R5 is CH 2 CH 3 ,

X is SO 2 , and

Y is (CH 2 ) p where p is 0

or a physiologically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

7. The method of claim 1 , wherein

R1 is H,

R2 is Cl,

R3 is H,

R4 is H,

R5 is CH(CH 3 ) 2 ,

X is SO 2 , and

Y is (CH 2 ) p where p is 0

or a physiologically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

8. The method according to claim 1 , wherein said at least one compound is administered in combination with at least one weight controlling active compound.

9. The method of claim 8 , wherein said at least one weight controlling active compound is chosen from cathine, phenylpropanolamine, amfepramone, mefenorex, ephedrine, leptin, dexamphetamine, amphetamine, fenfluramine, dexfenfluramine, sibutramine, orlistat, mazindol or phentermine or salts thereof.

10. A method for the treatment of obesity in a mammal comprising administering to a mammal in need thereof at least one compound chosen from at least one compound of the formula (I)

in which

R1, R2, R3, R4 independently of one another are H, F, Cl, Br, I, CN; N 3 , NO 2 , OH, O(C 1 -C 8 )-alkyl, O(C 3 -C 4 and C 6 -C 8 )-cycloalkyl, O—CH 2 -phenyl, O-phenyl, O—CO—(C 1 -C 8 )-alkyl, O—CO—(C 3 -C 8 )-cycloalkyl, S(O) 0-2 (C 1 -C 8 )-alkyl, S(O) 0-2 (C 3 -C 8 )-cycloalkyl, NH 2 , NH—(C 1 -C 8 )-alkyl, NH—(C 3 -C 8 )-cycloalkyl, N[(C 1 -C 8 )-alkyl] 2 , N[(C 3 -C 8 )-cycloalkyl] 2 , NH—CO—(C 1 -C 8 )-alkyl, NH—CO—(C 3 -C 8 )-cycloalkyl, SO 3 H, SO 2 —NH 2 , SO 2 —NH—(C 1 -C 8 )-alkyl, SO 2 —NH—(C 3 -C 8 )-cycloalkyl, NH—SO 2 —NH 2 , NH—SO 2 —(C 1 -C 8 )-alkyl, NH—SO 2 —(C 3 -C 8 )-cycloalkyl, O—CH 2 —COOH, O—CH 2 —CO—O(C 1 -C 8 )-alkyl, COOH, CO—O(C 1 -C 8 )-alkyl, CO—O—(C 3 -C 8 )-cycloalkyl, CO—NH 2 , CONH(C 1 -C 8 )-alkyl, CO—N[(C 1 -C 8 )-alkyl] 2 , (C 1 -C 8 )-alkyl, (C 3 -C 8 )-cycloalkyl, (C 2 -C 8 )-alkenyl, (C 2 -C 8 )-alkynyl, wherein the alkyl, cycloalkyl, alkenyl and alkynyl groups in each case have zero to seven hydrogen atoms replaced by fluorine, or one hydrogen may be replaced by OH, OC(O)CH 3 , O—CH 2 -Ph, NH 2 , NH—CO—CH 3 or N(COOCH 2 Ph) 2 ; or

phenyl, 1- or 2-naphthyl,

5-tetrazolyl,

1-[(C 1 -C 6 )-alkyl]-5-tetrazolyl,

2-[(C 1 -C 6 )-alkyl]-5-tetrazolyl;

1-imidazolyl,

1- or 4-[1,2,4]-triazolyl,

1- or 3-thienyl,

2- or 3-furyl,

2-, 3- or 4-pyridyl,

2-, 4- or 5-oxazolyl,

2-, 4- or 5-isoxazolyl,

2-, 4- or 5-thiazolyl,

2-, 4- or 5-isothiazolyl where the aryl radical or heterocycle is unsubstituted or substituted one to two times by F, Cl, Br, CN, OH, (C 1 -C 4 )-alkyl, CF 3 , O—(C 1 -C 4 )-alkyl, S(O) 0-2 (C 1 -C 6 )-alkyl, NH 2 , NH—SO 2 —(C 1 -C 4 )-alkyl, COOH, CO—O—(C 1 -C 4 )-alkyl, CO—NH 2 , wherein the alkyl groups in each case have zero to seven hydrogen atoms replaced by fluorine;

or R2 and R3 together form the group —O—CH 2 —O—;

X is S, SO, or SO 2 ;

Y is (CH 2 ) p , where p is 0, 1, 2 or 3;

R5 is CF 3 , (C 1 -C 18 )-alkyl, or (C 3 -C 8 )-cycloalkyl, wherein the alkyl groups in each case have zero to seven hydrogen atoms replaced by fluorine;

(CH 2 ) r COR6, where r is 1-6 and R6 is OH, O—(C 1 -C 6 )-alkyl or NH 2 ;

CH 2 —CH(NHR7)-COR8, where R7 is H, C(O)—(C 1 -C 4 )-alkyl or C(O)O—(C 1 -C 4 )-alkyl and R8 is OH, O—(C 1 -C 6 )-alkyl or NH 2 ; or

phenyl, 1- or 2-naphthyl, biphenyl or a heterocyclic radical, where the rings or ring systems are unsubstituted or substituted one or two times by F, Cl, Br, I, CN, OH, O(C 1 -C 8 )-alkyl, O(C 3 -C 8 )-cycloalkyl, O—CO—(C 1 -C 8 )-alkyl, O—CO—(C 3 -C 8 )-cycloalkyl, S(O) 0-2 (C 1 -C 8 )-alkyl, S(O) 0-2 (C 3 -C 8 )-cycloalkyl, NH 2 , NH—(C 1 -C 8 )-alkyl, NH—(C 3 -C 8 )-cycloalkyl, N[(C 1 -C 8 )-alkyl] 2 , N[(C 3 -C 8 )-cycloalkyl] 2 , NH—CO—(C 2 -C 8 )-alkyl, NH—CO—(C 3 -C 8 )-cycloalkyl, SO 3 H; SO 2 —NH 2 , SO 2 —NH—(C 1 -C 8 )-alkyl, SO 2 —NH—(C 3 -C 8 )-cycloalkyl, NH—SO 2 —NH 2 , NH—SO 2 —(C 1 -C 8 )-alkyl, NH—SO 2 —(C 3 -C 8 )-cycloalkyl, O—CH 2 —COOH, O—CH 2 —CO—O(C 1 -C 8 )-alkyl, COOH, CO—O(C 1 -C 8 )-alkyl, CO—O—(C 3 -C 8 )-cycloalkyl, CO—NH 2 , CONH(C 1 -C 8 )-alkyl, CO—N[(C 1 -C 8 )-alkyl] 2 , (C 1 -C 8 )-alkyl, (C 3 -C 8 )-cycloalkyl, where in the alkyl and cycloalkyl groups in each case have zero to seven hydrogen atoms replaced by fluorine;

or a physiologically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

11. The method of claim 10 , wherein

R1 is H,

R2 is Cl,

R3 is H,

R4 is H,

R5 is CH 3 ,

X is SO 2 , and

Y is (CH 2 ) p where p is 0

or a physiologically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

12. The method of claim 10 , wherein

R1 is H,

R2 is Cl,

R3 is H,

R4 is H,

R5 is CH 3 ,

X is S, and

Y is (CH 2 ) p where p is 0

or a physiologically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

13. The method of claim 10 , wherein

R1 is H,

R2 is Cl,

R3 is H,

R4 is H,

R5 is CH 2 CH 3 ,

X is SO 2 , and

Y is (CH 2 ) p where p is 0

or a physiologically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

14. The method of claim 10 , wherein

R1 is H,

R2 is Cl,

R3 is H,

R4 is H,

R5 is CH(CH 3 ) 2 ,

X is SO 2 , and

Y is (CH 2 ) p where p is 0

or a physiologically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

15. The method according to claim 10 , wherein said at least one compound is administered in combination with at least one weight controlling active compound.

16. The method of claim 15 , wherein said at least one weight controlling active compound is chosen from cathine, phenylpropanolamine, amfepramone, mefenorex, ephedrine, leptin, dexamphetamine, amphetamine, fenfluramine, dexfenfluramine, sibutramine, orlistat, mazindol or phentermine or salts thereof.

17. The method according to claim 1 , wherein said at least one compound is administered in combination with at least one antidiabetic compound.

18. The method of claim 17 , wherein said at least one antidiabetic compound is chosen from insulins, amylin GL-1 and GLP-2 derivatives, and oral hypoglycemic active compounds.

19. The method of claim 18 , wherein said oral hypoglycemic active compounds are chosen form sulfonyl ureas, biguanides, meglitinides, oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors, glucagon receptor antagonists, GLP-1 agonists, potassium channel openers, insulin sensitizers, activators of insulin receptor kinase, glycogen phosphorylase inhibitors, and modulators of glucose uptake and glucose elimination,

20. The method of claim 19 , wherein said sulfonylureas are chosen from tolbutamide, glibenclamide, glimepiride, glipizide, gliquidone, glisoxepide, glibornuride and gliclazide.

21. The method according to claim 1 , wherein said at least one compound is administered in combination with at least one additional compound chosen from antihyperlipidemic active compounds and antilipidemic active compounds.

22. The method according to claim 21 , wherein said at least one additional compound is chosen from cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, probucol, ezetimibe and dextrothyroxine.

23. The method according to claim 1 , wherein said at least one compound is administered in combination with at least one antihypertensive active compound.

24. The method according to claim 23 , wherein said at least one antihypertensive active compound is chosen from betablockers, ACE (angiotensin-converting enzyme) inhibitors, calcium channel blockers and alpha blockers.